Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation.
This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.
- Male and/or female (without childbearing potential) white patients - History of persistent or permanent atrial fibrillation - 18 to 75 years of age
- Patients with high-risk cardiovascular diseases - Stroke or myocardial infarction - Relevant pathological changes in the ECG or echocardiography - Medication affecting ventricular response in Afib
CardioSec Clinical Research GmbH
Erfurt, Germany, 99084
E-mail: [email protected]
Phone: Not Available
Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days
Single Group Assignment